人表皮生长因子受体2阳性胃癌治疗的挑战与未来

Ma Chenzhe, Wang Xiao, Guo Jiwu, Yang Bo, Li Yumin

The Second Clinical Medical College, Lanzhou University, Lanzhou, China.

Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China.

Front Oncol. 2023 Jan 30;13:1080990. doi: 10.3389/fonc.2023.1080990. eCollection 2023.

Gastric cancer is the fifth most common cancer worldwide, and the treatment of advanced gastric cancer has relatively little progress. With the continuous development of molecularly targeted therapy for tumors, it has been discovered that human epidermal growth factor receptor 2 (HER2) contributes to the poor prognosis and pathogenesis of various cancers. In order to treat HER2-positive advanced gastric cancer, Trastuzumab has emerged as the first first-line targeted medication used in conjunction with chemotherapy. The consequent trastuzumab resistance has become an important issue, and various new HER2-targeted gastric cancer drugs are emerging to address this challenge. This review's primary concern is the drug mechanism of various HER2-positive gastric cancer targeted therapy and fresh techniques of detection.

胃癌是全球第五大常见癌症，晚期胃癌的治疗进展相对较少。随着肿瘤分子靶向治疗的不断发展，人们发现人类表皮生长因子受体2（HER2）导致多种癌症的预后不良和发病机制。为了治疗HER2阳性晚期胃癌，曲妥珠单抗已成为第一种与化疗联合使用的一线靶向药物。随之而来的曲妥珠单抗耐药性已成为一个重要问题，各种新型HER2靶向胃癌药物正在涌现以应对这一挑战。本综述主要关注各种HER2阳性胃癌靶向治疗的药物机制和新的检测技术。